R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves single or multi-hospital healthcare systems, and their respective affiliated ambulatory clinics and physician practice groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Industry, Sector and Symbol
Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
SymbolNASDAQ:RCM
CUSIP00438V10
Phone312-324-7820
Debt
Debt-to-Equity RatioN/A
Current Ratio2.23
Quick Ratio2.23
Price-To-Earnings
Trailing P/E Ratio-19.36
Forward P/E Ratio-50.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$449.80 million
Price / Sales2.08
Cash FlowN/A
Price / CashN/A
Book Value$0.32 per share
Price / Book26.63
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$-58,800,000.00
Net Margins-14.47%
Return on Equity-45.77%
Return on Assets-7.12%
Miscellaneous
Employees9,965
Outstanding Shares109,660,000
R1 RCM (NASDAQ:RCM) Frequently Asked Questions
What is R1 RCM's stock symbol?
R1 RCM trades on the NASDAQ under the ticker symbol "RCM."
How were R1 RCM's earnings last quarter?
R1 RCM (NASDAQ:RCM) issued its earnings results on Wednesday, May, 9th. The financial services provider reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.11. The financial services provider earned $147.30 million during the quarter, compared to analysts' expectations of $146 million. R1 RCM had a negative return on equity of 45.77% and a negative net margin of 14.47%. View R1 RCM's Earnings History.
When is R1 RCM's next earnings date?
What price target have analysts set for RCM?
3 brokerages have issued twelve-month target prices for R1 RCM's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate R1 RCM's share price to reach $9.3333 in the next year. View Analyst Ratings for R1 RCM.
What are Wall Street analysts saying about R1 RCM stock?
Here are some recent quotes from research analysts about R1 RCM stock:
- 1. According to Zacks Investment Research, "R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. " (6/15/2018)
- 2. Cantor Fitzgerald analysts commented, "The revenue cycle management market represents a significant opportunity. Revenue cycle management remains an underdeveloped and fragmented market. There are many different solutions available, including consulting arrangements, point-solution technologies, and transactional outsourcing. Many providers use fragmented solutions. As a result, healthcare organizations are increasingly dissatisfied with currently available options and see a strong commercial partner to help improve performance and increase ROI. We estimate the market opportunity will increase to almost $70 billion by 2020. In addition, increasing consolidation among providers should lead to additional outsourcing. We expect revenue cycle outsourcing to grow to $7.7 billion by 2020 from $3.8 billion in 2015. We estimate the ambulatory market opportunity is approximately $30-40 billion. As hospital systems acquire physician offices, we expect the ambulatory market opportunity to expand." (3/13/2018)
Who are some of R1 RCM's key competitors?
Who are R1 RCM's key executives?
R1 RCM's management team includes the folowing people:
- Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 47)
- Mr. Christopher Simon Ricaurte, CFO & Treasurer (Age 58)
- Mr. Thomas A. Lesica, Exec. VP of Bus. Transformation (Age 58)
- Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 48)
- Mr. Richard B. Evans Jr., Principal Accounting Officer, Sr. VP and Corp. Controller (Age 50)
Has R1 RCM been receiving favorable news coverage?
News stories about RCM stock have been trending somewhat negative this week, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. R1 RCM earned a daily sentiment score of -0.02 on Accern's scale. They also gave media headlines about the financial services provider an impact score of 44.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are R1 RCM's major shareholders?
R1 RCM's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include TCP-ASC ACHI SERIES LLLP (59.80%), BlackRock Inc. (5.03%), JASPER RIDGE PARTNERS, L.P. (3.00%), Eversept Partners LLC (1.74%), Dimensional Fund Advisors LP (0.76%) and Balter Liquid Alternatives LLC (0.59%). Company insiders that own R1 RCM stock include Alex Mandl, John B Henneman III and Joseph Gerard Flanagan. View Institutional Ownership Trends for R1 RCM.
Which major investors are selling R1 RCM stock?
RCM stock was sold by a variety of institutional investors in the last quarter, including SLS Management LLC, Wells Fargo & Company MN, Unterberg Capital LLC, California Public Employees Retirement System and MetLife Investment Advisors LLC. View Insider Buying and Selling for R1 RCM.
Which major investors are buying R1 RCM stock?
RCM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., 22NW LP, Dimensional Fund Advisors LP, Eversept Partners LLC, Millennium Management LLC, EAM Global Investors LLC, JPMorgan Chase & Co. and Balter Liquid Alternatives LLC. Company insiders that have bought R1 RCM stock in the last two years include Alex Mandl, John B Henneman III and Joseph Gerard Flanagan. View Insider Buying and Selling for R1 RCM.
How do I buy shares of R1 RCM?
Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is R1 RCM's stock price today?
One share of RCM stock can currently be purchased for approximately $8.52.
How big of a company is R1 RCM?
R1 RCM has a market capitalization of $944.15 million and generates $449.80 million in revenue each year. The financial services provider earns $-58,800,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. R1 RCM employs 9,965 workers across the globe.
How can I contact R1 RCM?
R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The financial services provider can be reached via phone at 312-324-7820 or via email at [email protected]
MarketBeat Community Rating for R1 RCM (RCM)
MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote "Outperform" if you believe RCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
